Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era
Minisini AM et al. - In a trial to retrospectively analyze the incidence of amenorrhea after adjuvant chemotherapy and subsequent recovery of menses in 145 breast cancer pts, it was determined that recovery of menses after chemotherapy-induced amenorrhea occurs more probably in younger women, with no pregnancies and receiving taxanes. Methods- Incidence of amenorrhea after adjuvant chemotherapy and subsequent recovery of menses were analyzed in 145 breast cancer pts.
- Age, smoking, alcohol consumption, body mass index, chemotherapy regimen, previous hormonal therapies, and previous childbearing were analyzed as potential predictive factors of ovarian function recovery.
Results- Median age was 42 yrs at the beginning of adjuvant chemotherapy with 30.3% of pts below 40 yrs of age.
- The majority (87.6%) of pts received anthracycline-based chemotherapy, 35.2% of pts received a cyclophosphamide-methotrexate-5-fluorouracil regimen, and 42.8% received a taxane.
- Incidence of chemotherapy-induced amenorrhea was 80, and 35.3% of these pts resumed menses after a median of 8 mos.
- Younger age (<40 yrs) and taxane-based chemotherapy were associated with increased probability of recovery of menses after chemotherapy-induced amenorrhea.
- Cyclophosphamide-methotrexate-5-fluorouracil-based chemotherapy and previous childbearing were associated with an increased probability of permanent chemotherapy-induced amenorrhea.
[more...]
|
|
|
